WallStSmart

IDEXX Laboratories Inc (IDXX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 935% more annual revenue ($44.56B vs $4.30B). IDXX leads profitability with a 24.6% profit margin vs 15.0%. TMO appears more attractively valued with a PEG of 1.76. TMO earns a higher WallStSmart Score of 62/100 (C+).

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 4.7Quality: 5.0
Piotroski: 5/9

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IDXXSignificantly Overvalued (-40.3%)

Margin of Safety

-40.3%

Fair Value

$462.49

Current Price

$577.26

$114.77 premium

UndervaluedFair: $462.49Overvalued
TMOSignificantly Overvalued (-23.4%)

Margin of Safety

-23.4%

Fair Value

$384.60

Current Price

$474.39

$89.79 premium

UndervaluedFair: $384.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IDXX3 strengths · Avg: 9.0/10
Return on EquityProfitability
66.2%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$176.23B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
4.022/10

Expensive relative to growth rate

P/E RatioValuation
44.2x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.7x2/10

Trading at 28.7x book value

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
26.7x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 44.2x leaves little room for execution misses.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

IDXX profiles as a mature stock while TMO is a value play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.70 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 61/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?